Source: BEFREE

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Making use of the tumoral TGFB1 signaling network in the context of MSC-mediated NIS gene delivery is a promising approach to foster tumor stroma-selectivity of NIS transgene expression and tailor NIS-based gene therapy to TGFB1-rich tumor environments. 30121623

2019

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Increased expression of the cell surface receptor c-Met, the glucose transporter GLUT-1 and the sodium iodide symporter lead to tumour growth, angiogenesis and cell migration. 30819129

2019

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Recent studies have described important roles for the sodium iodide symporter (NIS) in tumor behavior. 30191346

2019

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Combination of EBRT and SMAD-NIS-MSC-mediated <sup>131</sup>I therapy resulted in a significantly improved delay in tumor growth and prolonged survival in therapy mice as compared with the combined therapy using CMV-NIS-MSCs or to control groups receiving EBRT or saline only, or EBRT together with SMAD-NIS-MSCs and saline applications. 31196853

2019

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Ultimately, combining BLI and NIS imaging represented a significant enhancement over traditional BLI, providing more information about tumor size and location. 30674994

2019

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE In conclusion, the dual-targeting approach highlights the benefits of a bifunctional strategy for a future clinical translation of the bioimaging-based NIS-mediated radiotherapy allowing efficient targeting of heterogeneic tumors with variable receptor expression levels. 30683895

2019

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Active MSC recruitment into the tumor stroma was confirmed using NIS immunohistochemistry (IHC). 30224540

2019

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Synthesis and evaluation of <sup>18</sup>F-hexafluorophosphate as a novel PET probe for imaging of sodium/iodide symporter in a murine C6-glioma tumor model. 29198608

2018

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Furthermore, we evaluated enhancement of NIS promoter and therapeutic efficacy of RAI in ATC tumour xenograft mice. 29467951

2018

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE We aimed to evaluate if NIS expression in thyroid primary tumors would be helpful in predicting tumor behavior, response to therapy and prognosis. 29298843

2018

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE Further clinical evaluation as a PET tracer for imaging thyroid pathophysiology and human sodium/iodide symporter expressing neoplasms is highly warranted. 29356744

2018

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE NIS repression by activated p53 is further confirmed by non-invasive bioluminescence imaging in live cell and orthotropic tumor model. 28528452

2017

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE These results clearly demonstrate that systemic in vivo NIS gene transfer using nanoparticle vectors coupled to B6 tumor targeting ligand is capable of inducing tumor-specific radioiodide uptake. 28423213

2017

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Oncolytic VSV engineered to express interferon-beta (IFNβ) and the sodium iodide symporter (NIS), VSV-IFNβ-NIS, has been shown to be a potent new therapeutic agent inducing rapid and durable tumor remission following systemic therapy in preclinical mouse models. 28514874

2017

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors. 27635026

2017

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Administration of a therapeutic dose of 131I in mice treated with NIS-transfected MSCs resulted in delayed tumor growth and reduced tumor perfusion, as shown by contrast-enhanced sonography, and significantly prolonged survival of mice bearing orthotopic HCC tumors. 27458162

2016

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE Immunohistochemical staining showed that HeLa-TERTNIS xenograft tumors expressed higher levels of NIS and caspase-3 and lower levels of Ki-67 than HeLa xenograft tumors. 27573304

2016

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Oncolytic VSV-IFNβ-NIS is selectively destructive to tumors. 27532609

2016

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE Imaging for NIS expression showed robust virus infection within the tumors. 26712908

2016

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE 131I treatment reduced tumor sizes of hNIS- and opt-hNIS-expressing tumors to 0.57- and 0.27- fold, respectively, compared to their sizes before therapy, suggesting an improved therapeutic effect of opt-hNIS. 25553100

2015

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Local administration of MV-NIS into MPNST-derived tumors resulted in significant regression of tumor and improved survival. 25843626

2015

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE In xenograft tumor models, uptake of (99m)TcO4 (-) was obviously higher in the hNIS and rNIS groups compared with controls. 26115738

2015

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE To expand the potential range of tumor targets, we investigated the biodistribution and tumor recruitment of MSCs transfected with NIS under control of the RANTES/CCL5 promoter (RANTES-NIS-MSC) in a colon cancer liver metastasis mouse model established by intrasplenic injection of the human colon cancer cell line LS174t. 25745085

2015

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 GeneticVariation BEFREE The NGS data revealed the coexisting of a well-characterized loss-of-function TP53 R248Q mutation and a putative gain-of-function mutation of TSHR L272V, which was suggested by the overexpression of thyroglobulin and SLC5A5 (NIS) genes in this tumor. 26260781

2015

Entrez Id: 6528
Gene Symbol: SLC5A5
SLC5A5
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Given the recent progress in the study of NIS regulation as molecular basis for new therapeutic approaches in extrathyroidal cancers, particular attention is given to studies regarding the relationship between NIS and clinical-pathological aspects of the tumors and the regulation of NIS expression in the experimental models. 24884806

2014